Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)

CUSIP: 71722W107

Q2 2020 13F Holders as of 30 Jun 2020

Holder snapshot 6 signals
Share change
-101,372
SEC-reported price per share
$32.91
Indexed holders
59
Value change
-$3,025,534
Number of buys
40
Number of sells
11
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
81,261,176

Security key

71722W107

Report period

Q2 2020

Indexed institutions

59

Top holders

10

Ownership snapshot

Top reported holders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FRAZIER MANAGEMENT LLC
Disclosed value leader
FRAZIER MANAGEMENT LLC
Comparable rows
0/15
Latest evidence
31 Mar 2020
13F Highest disclosed value: $188,080,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

FRAZIER MANAGEMENT LLC has the largest disclosed position value at $188.08M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FRAZIER MANAGEMENT LLC's linked filing trail.
Disclosed position value Top 5
FRAZIER MANAGEMENT LLC $188.08M
RA CAPITAL MANAGEMENT, L.P. $95.72M
Invesco Ltd. $53.59M
Medicxi Ventures Management (Jers... $53.39M
Janus Henderson Group Ltd. $42.18M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FRAZIER MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$188,080,000
7,284,269 shares
— 31 Mar 2020
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$95,725,000
3,707,408 shares
— 31 Mar 2020
Invesco Ltd.
13F
Company
13F
—
denominator unverified
$53,594,000
2,075,685 shares
— 31 Mar 2020
Medicxi Ventures Management (Jersey) Ltd
13F
Company
13F
—
denominator unverified
$53,392,000
2,067,861 shares
— 31 Mar 2020
Janus Henderson Group Ltd.
13F
Company
13F
—
denominator unverified
$42,175,000
1,667,577 shares
— 31 Mar 2020
Abingworth LLP
13F
Company
13F
—
denominator unverified
$30,824,000
1,203,135 shares
— 31 Mar 2020
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2020

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
59
Shares
21,847,152
Indexed holders
59
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 indexed holders
47
Q2 2020 indexed holders
59
Indexed holder difference
12
Investor Q1 2020 Shares Q2 2020 Shares Share Diff Share Chg % Q1 2020 value Q2 2020 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .